Cardinal Health reported first-quarter fiscal 2027 revenue of $67.5 billion, a 5% increase year-over-year, alongside a GAAP diluted EPS of $2.38. Driven by strong segment performance, the company raised its full-year non-GAAP diluted EPS guidance range to $12.80 to $13.00 and completed a $500 million share repurchase program.
First-quarter revenue increased 5% to $67.5 billion compared to the prior-year period.
GAAP diluted EPS grew 27% to $2.38 and non-GAAP diluted EPS grew 28% to $3.26.
Fiscal year 2027 non-GAAP EPS guidance was raised to a range of $12.80 to $13.00.
The company completed its $500 million share repurchase program during the first quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Cardinal Health's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2026
$254.25B
+14.2%
$7.23
+12.1%
0.7%
FY2025
$222.58B
-1.9%
$6.45
+87.0%
0.7%
FY2024
$226.83B
+10.7%
$3.45
+173.8%
0.4%
FY2023
$204.98B
+13.0%
$1.26
—
0.2%
FY2022
$181.33B
+11.6%
$-3.37
-262.0%
-0.5%
Frequently asked questions
When is Cardinal Health's next earnings date?
Cardinal Health has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Cardinal Health earn last quarter?
For the quarter ended Sep 2026, Cardinal Health reported diluted EPS of $2.38 on revenue of $67.51B (+23.0%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.